Acromegaly

Metabolism: Clinical and Experimental

Volumn 45, Issue SUPPL.1, 1996, Pages 51-52

  Melmed, Shlomo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ARTICLE; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; MORTALITY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME;

ACROMEGALY; ADENOMA; GROWTH HORMONE; HUMANS; OCTREOTIDE; PITUITARY NEOPLASMS;

EID: 0029786520     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90081-5     Document Type: Article

References (5)

1. Melmed S, Ho K, Klibanski A, et al: Recent advances in pathogenesis, diagnosis and management of acromegaly. J Clin Endocrinol Metab 80:3395-3402, 1995
2. Melmed S, Dowling RH, Frohman L, et al: Consensus statement: benefits versus risks of medical therapy for acromegaly. Am J Med 97:468-473, 1994
3. Newman CB, Melmed S, Snyder PJ, et al: Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study. J Clin Endocrinol Metab 80:2768-2775, 1995
4. Lancranjan I, Bruns C, Grass P, et al: Sandostatin® LAR® pharmacokinetics, pharmacodynamics, efficacy and tolerability in acromegalic patients. Metab Clin Exp 44:18-26, 1995 (suppl 1)
5. Frohman LA: Acromegaly: What constitutes optimal therapy? J Clin Endocrinol Metab 81:443-445, 1996 (editorial)